InvestorsHub Logo
Post# of 252302
Next 10
Followers 833
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 27709

Saturday, 12/16/2006 2:43:08 PM

Saturday, December 16, 2006 2:43:08 PM

Post# of 252302
Update on Biolex program in HCV:

The RBC panel on anti-infectives included Biolex, a private company based in North Carolina that is developing a long-acting formulation of interferon-alpha called Locteron manufactured in transgenic plants (#msg-10846766).

Biolex claims the underlying interferon molecule in Locteron is structurally identical to SGP’s Intron-A, which is non-glycosylated. The Locteron interferon is attached to two polymers that continuously release the interferon over time; Biolex claims that this continuous release avoids the burst effect seen with Peg-Intron and Pegasys that is responsible in large measure for the flu-like symptoms of those drugs.

The phase-2 Locteron trial appears to be a little late getting started; Biolex now expects to release 12-week viral-load data in 2Q07.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.